Site Search

1. 261.
   AMP/assets/File/position-statements/2015/FDAcommentsonLDTguidance-FINAL.pdf?pass...

   cancer occur less than 1% of the time. For example, while lung adenocarcinomas have a rather high incidence, some targetable subtypes are rare and these subtypes should be considered rare and eligible for any rare disease exemption. For these reasons, AMP proposes that a test should be classified as a rare disease LDP if a test is intended to test a variant

   https://www.amp.org/AMP/assets/File/position-statements/2015/FDAcommentsonLDTgui...
2. 262.
   AMP/assets/File/education/case-studies/0520_42-46_AMPcase-LowRes.pdf?pass=84

   T) at a low variant allelic frequency (VAF) (Fig. 2F). Due to the paucity of the large tumor cells and the prominent lymphocytic and necrotic background, we performed manual review of the hotspot V600E in BRAF and identified a variant (NM_004333 (BRAF):c.1799T>A p.V600E) below the lower limit of detection at two percent VAF that was considered a true

   https://www.amp.org/AMP/assets/File/education/case-studies/0520_42-46_AMPcase-Lo...
3. 263.
   AMP/assets/File/clinical-practice/0324_26-27_AMPcase-Ansar-reprint_HiRes.pdf?pass=...

   FISH assays for 5q deletion and trisomy 8 were positive (Figs. 3a and 3b). NPM1, FLT3-ITD, and D835 mutations by conventional PCR were not detected. The ... marrow karyotype: 52~58, XY, add(6)(q27)[16]/46,XY[04]Normal karyotype52~58 hyperdiploidyHyperdiploidy karyotypeFig. 3a. FISH trisomy 8Fig. 3b. FISH 5q Del CAP TODAY|34. Rea B, Aggarwal N, Yatsenko SA, Bailey

   https://www.amp.org/AMP/assets/File/clinical-practice/0324_26-27_AMPcase-Ansar-r...
4. 264.
   AMP/assets/File/education/MIMP/CentralNervousSystem.pdf?pass=30

   V600 mutations and fusions are targetable. NGS, genotyping, PCR-based assays, IHC, RT-PCR, AMP H3-3A (H3F3A) H3C2 (HIST1H3B) Alterations in codons K28 (K27) or G35 (G34) ... Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6). https://publications.iarc.fr/601. “Molecular in My Pocket” reference cards are educational resources

   https://www.amp.org/AMP/assets/File/education/MIMP/CentralNervousSystem.pdf?pass...
5. 265.
   AMP/assets/File/education/MolecularPathologyResourcesforTeaching.pdf?pass=56

   Apps like "top hat" for interactive quizzes https://tophat.com/classroom/classroom-app/ ... be great for technologists to review. https://educate.amp.org/local/catalog/view ... Published 12/3/21 CAP lectures: https://learn.cap.org/lms/home AMP ... cases to use as examples https://www.captodayonline.com/category/amp ... PCR and the actual sequencing https://www.youtube.com/watch

   https://www.amp.org/AMP/assets/File/education/MolecularPathologyResourcesforTeac...
6. 266.
   AMP/assets/File/clinical-practice/0225_22-24_AMPcase-Zhang_reprint-HiRes.pdf?pass=...

   CAP TODAY|3patient’s tumor, which may provide a more definitive diagnosis (Fig. 3A).8 Briefly, RNA was extracted from formalin-fixed, paraffin-embedded tumor tissues and quantified. cDNA library was prepared from the extracted RNA using the Anchored Multiplex PCR technology and custom-designed gene-specific primers and sequenced. Fusion genes were

   https://www.amp.org/AMP/assets/File/clinical-practice/0225_22-24_AMPcase-Zhang_r...
7. 267.
   AMP/assets/File/education/MGP25/MGP25_ProgramBook.pdf?pass=89

   This course is free for AMP members. https://bit.ly/3D5vn6f MOLECULAR LABORATORY ... is offered free for everyone. https://bit.ly/AMPLabMgt RESOURCES REVIEW ... are free for AMP members. https://bit.ly/AMPFlash This course ... is free for AMP members. https://bit.ly/AMPNGSv2 NGS101 v2.0 ... be notified when registration opens: https://www.surveymonkey.com/r/NSGM9ZM

   https://www.amp.org/AMP/assets/File/education/MGP25/MGP25_ProgramBook.pdf?pass=8...
8. 268.
   AMP/assets/File/position-statements/2019/CAP_AMP_Comments_Noridian_DL38335_DL38337...

   in FDA-labeling1, to 1 https://www.fda.gov/drugs/ ... 5, and *6 to 2 https://cpicpgx.org/guidelines/3 https://www.pharmgkb.org/page/dpwg 4 https://www.pharmgkb.org/5 https://www.pharmvar.org/gene/CYP2D6 ... 1578(18)30594-4/fulltext 8 https://cpicpgx.org/content/guideline/publication/voriconazole ... DPYD 81232 G6PD 81247 9 https://cpicpgx.org/genes-drugs/ UGT1A1

   https://www.amp.org/AMP/assets/File/position-statements/2019/CAP_AMP_Comments_No...
9. 269.
   AMP/assets/File/position-statements/2019/CAP_AMP_Comments_Palmetto_DL38294_11-21...

   in FDA-labeling1, to 1 https://www.fda.gov/drugs/ ... 5, and *6 to 2 https://cpicpgx.org/guidelines/3 https://www.pharmgkb.org/page/dpwg 4 https://www.pharmgkb.org/5 https://www.pharmvar.org/gene/CYP2D6 ... 1578(18)30594-4/fulltext 8 https://cpicpgx.org/content/guideline/publication/voriconazole ... DPYD 81232 G6PD 81247 9 https://cpicpgx.org/genes-drugs/ UGT1A1

   https://www.amp.org/AMP/assets/File/position-statements/2019/CAP_AMP_Comments_Pa...
10. 270.
    AMP/assets/File/position-statements/2019/CAP_AMP_Comments_CGS_DL38394_11-21-2019...

    policies for additional genes. 1 https://www.fda.gov/drugs/ ... 1.4 percent of African-2 https://cpicpgx.org/guidelines/3 https://www.pharmgkb.org/page/dpwg 4 https://www.pharmgkb.org/5 https://www.pharmvar.org/gene/CYP2D6 ... 18)30594-4/fulltext 8 https://cpicpgx.org/content/guideline/publication ... G6PD 81247 UGT1A1 81350 9 https://cpicpgx.org/genes-drugs/ HLA

    https://www.amp.org/AMP/assets/File/position-statements/2019/CAP_AMP_Comments_CG...